MBT Financial Corp. (MBTF) At $10.50 Forms Top; Last Week Alliqua BioMedical, Inc. (ALQA) Analysts

MBT Financial Corp. (NASDAQ:MBTF) Logo

MBT Financial Corp. (MBTF) formed multiple top with $11.13 target or 6.00% above today’s $10.50 share price. MBT Financial Corp. (MBTF) has $241.17M valuation. The stock increased 0.96% or $0.1 during the last trading session, reaching $10.5. About 31,138 shares traded. MBT Financial Corp. (NASDAQ:MBTF) has declined 0.96% since April 5, 2017 and is downtrending. It has underperformed by 12.51% the S&P500.

Among 3 analysts covering Alliqua Biomedical (NASDAQ:ALQA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Alliqua Biomedical had 12 analyst reports since August 19, 2015 according to SRatingsIntel. As per Friday, April 7, the company rating was maintained by H.C. Wainwright. RBC Capital Markets maintained it with “Outperform” rating and $3 target in Wednesday, February 24 report. H.C. Wainwright maintained Alliqua BioMedical, Inc. (NASDAQ:ALQA) rating on Wednesday, August 10. H.C. Wainwright has “Buy” rating and $2.50 target. The rating was maintained by Chardan Capital Markets on Friday, November 6 with “Buy”. The stock of Alliqua BioMedical, Inc. (NASDAQ:ALQA) earned “Buy” rating by H.C. Wainwright on Monday, November 2. H.C. Wainwright maintained the shares of ALQA in report on Wednesday, January 3 with “Buy” rating. The stock has “Hold” rating by Zacks on Wednesday, August 19. The company was maintained on Wednesday, February 24 by Chardan Capital Markets. The rating was maintained by RBC Capital Markets on Friday, November 6 with “Outperform”. The firm has “Neutral” rating by H.C. Wainwright given on Monday, January 8. See Alliqua BioMedical, Inc. (NASDAQ:ALQA) latest ratings:

08/01/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $1.5 Downgrade
03/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.5 Maintain

The stock decreased 1.01% or $0.02 during the last trading session, reaching $1.96. About 30,967 shares traded. Alliqua BioMedical, Inc. (NASDAQ:ALQA) has declined 69.15% since April 5, 2017 and is downtrending. It has underperformed by 80.70% the S&P500.

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company has market cap of $9.81 million. It markets MIST Ultrasound Healing Therapy, a painless, noncontact, low-frequency ultrasound to promote healing; Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix that are human biologic regenerative technologies; and TheraBond 3D Antimicrobial Barrier Systems that promotes an optimal wound healing by creating an antimicrobial barrier that helps protect against infection. It currently has negative earnings. The firm also provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

Since February 12, 2018, it had 3 buys, and 0 selling transactions for $108,148 activity. 4,499 shares were bought by DALY JOSEPH S, worth $46,880 on Thursday, February 15. On Thursday, March 8 the insider MILLER MICHAEL JAMES bought $51,000.

MBT Financial Corp. (NASDAQ:MBTF) Institutional Positions Chart